Diametric Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Diametric Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-39,778	Closed	-$80K	–	162
2020 Q1	$80K	Buy	+39,778	New	+$110K	0.1%	111

Other funds holding BCRX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Diametric Capital's BCRX Position: Q2 2020 in Review

Diametric Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2020, closing a stake of 39,778 shares — an estimated $80K sold.

Diametric Capital first reported a position in BCRX in Q1 2020 and held it in 1 quarter. The position peaked at $80K in Q1 2020. 165 funds tracked by Wall St. Rank hold BCRX as of Q2 2020.

Diametric Capital reported no remaining BioCryst Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Diametric Capital sold 39,778 BioCryst Pharmaceuticals shares in Q2 2020, an estimated $80K.
Diametric Capital first reported a position in BioCryst Pharmaceuticals in Q1 2020 and held it in 1 quarter.
Diametric Capital's BioCryst Pharmaceuticals position peaked at $80K in Q1 2020.
165 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2020.

Based on Diametric Capital's 13F filing for Q2 2020, filed 14 Aug 2020.